These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 21669012)

  • 1. Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    Loupakis F; Ruzzo A; Salvatore L; Cremolini C; Masi G; Frumento P; Schirripa M; Catalano V; Galluccio N; Canestrari E; Vincenzi B; Santini D; Bencardino K; Ricci V; Manzoni M; Danova M; Tonini G; Magnani M; Falcone A; Graziano F
    BMC Cancer; 2011 Jun; 11():247. PubMed ID: 21669012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive value of VEGF gene polymorphisms for metastatic colorectal cancer patients receiving first-line treatment including fluorouracil, irinotecan, and bevacizumab.
    Formica V; Palmirotta R; Del Monte G; Savonarola A; Ludovici G; De Marchis ML; Grenga I; Schirru M; Guadagni F; Roselli M
    Int J Colorectal Dis; 2011 Feb; 26(2):143-51. PubMed ID: 21188390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
    Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
    Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Crea F; Fornaro L; Paolicchi E; Masi G; Frumento P; Loupakis F; Salvatore L; Cremolini C; Schirripa M; Graziano F; Ronzoni M; Ricci V; Farrar WL; Falcone A; Danesi R
    Ann Oncol; 2012 May; 23(5):1207-1213. PubMed ID: 21926398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
    Stintzing S; Wirapati P; Lenz HJ; Neureiter D; Fischer von Weikersthal L; Decker T; Kiani A; Kaiser F; Al-Batran S; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Moehler M; Scheithauer W; Held S; Modest DP; Jung A; Kirchner T; Aderka D; Tejpar S; Heinemann V
    Ann Oncol; 2019 Nov; 30(11):1796-1803. PubMed ID: 31868905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A; Samalin E; Mitry E; Assenat E; Boyer-Gestin C; Lepère C; Bachet JB; Portales F; Vaillant JN; Ychou M; Rougier P
    BMC Cancer; 2009 Sep; 9():347. PubMed ID: 19785749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
    Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
    Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer.
    Suzuki T; Shinozaki E; Osumi H; Nakayama I; Ota Y; Ichimura T; Ogura M; Wakatsuki T; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    Cancer Chemother Pharmacol; 2019 Aug; 84(2):307-313. PubMed ID: 31065729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
    Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
    Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
    Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.
    Gerger A; El-Khoueiry A; Zhang W; Yang D; Singh H; Bohanes P; Ning Y; Winder T; Labonte MJ; Wilson PM; Benhaim L; Paez D; El-Khoueiry R; Absenger G; Lenz HJ
    Clin Cancer Res; 2011 Sep; 17(17):5783-92. PubMed ID: 21791631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms.
    Bécouarn Y; Cany L; Pulido M; Beyssac R; Texereau P; Le Morvan V; Béchade D; Brunet R; Aitouferoukh S; Lalet C; Mathoulin-Pélissier S; Fonck M; Robert J
    BMC Res Notes; 2014 Apr; 7():260. PubMed ID: 24758527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in first-line therapy of metastatic colorectal cancer: a retrospective comparison of FOLFIRI and XELIRI.
    Ocvirk J; Rebersek M; Boc M
    Anticancer Res; 2011 May; 31(5):1777-82. PubMed ID: 21617239
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G).
    Izawa N; Shitara K; Yonesaka K; Yamanaka T; Yoshino T; Sunakawa Y; Masuishi T; Denda T; Yamazaki K; Moriwaki T; Okuda H; Kondoh C; Nishina T; Makiyama A; Baba H; Yamaguchi H; Nakamura M; Hyodo I; Muro K; Nakajima TE
    Target Oncol; 2020 Oct; 15(5):623-633. PubMed ID: 32960408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
    Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
    Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
    Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
    Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
    Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
    Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.